微小RNA与血小板的关系研究进展

doi:10.3969/j.issn.1673-8640.2016.011.016

摘要/Abstract

摘要：

微小RNA（miRNA）是一类长度约为22nt的小分子非编码单链RNA,其功能主要是在转录后水平对基因表达进行调节,从而参与众多生命活动的调控。无核的血小板在止血和凝血过程中起着重要的作用,深入了解miRNA 在血小板生成和活化中的作用,将为血小板相关的血液系统性疾病的治疗提供了新的思路。

关键词: 血小板, 微小RNA, 生成, 活化

Abstract:

MicroRNA（miRNA） is 22-nucleotide noncoding single-stranded RNA. Its main function is to regulate gene expression after transcription,so as to participate in regulating biologic activity. Though platelet has no cell nucleus,it plays an important role in hemostasis and coagulation processes. Understanding the role of platelet production and activity deeply will provide new ideas for the treatment of platelet-related blood systemic diseases.

Key words: Platelet, MicroRNAs, Generation, Activation

中图分类号:

R446.1

陈淑英, 时朝辉, 林勇. 微小RNA与血小板的关系研究进展[J]. 检验医学, 2016, 31(11): 997-1001.

CHEN Shuying, SHI Chaohui, LIN Yong. Research progress of the relationship between microRNA and platelet[J]. Laboratory Medicine, 2016, 31(11): 997-1001.

图/表 2

参考文献 35

1	WONG MC,ZHANG DE X,WANG HH.Rapid emergence of atherosclerosis in Asia:a systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies[J]. Curr Opin Lipidol,2015,26(4):257-269.
2	DAI W,LI Y,LV YN,et al.The roles of a novel anti-inflammatory factor,milk fat globule-epidermal growth factor 8,in patients with coronary atherosclerotic heart disease[J]. Atherosclerosis,2014,233(2):661-665.
3	AVERT Trial Collaboration Group,BERNHARDT J,LANQHORNE P,et al. Efficacy and safety of very early mobilisation within 24 h of stroke onset(AVERT):a randomised controlled trial[J]. Lancet,2015,386(9988):46-55.
4	MÜLLER KA,KARATHANOS A,TAVLAKI E,et al. Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy[J]. Platelets,2014,25(6):439-446.
5	SHI R,ZHOU X,JI WJ,et al.The emerging role of miR-223 in platelet reactivity:implications in antiplatelet therapy[J]. Biomed Res Int,2015,2015:981841.
6	NAQALLA S,SHAW C,KONG X,et al.Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity[J]. Blood,2011,117(19):5189-5197.
7	SCHIRLE NT,SHEU-GRUTTADAURIA J,MACRAE IJ.Structural basis for microRNA targeting[J]. Science,2014,346(6209):608-613.
8	CARRINGTON JC,AMBROS V.Role of microRNAs in plant and animal development[J]. Science,2003,301(5631):336-338.
9	覃基政,蒋青. microRNA调控血小板生成及功能[J]. 医学分子生物学杂志,2012,9(2):136-139.
10	SCHMIEDEL JM,KLEMM SL,ZHENG Y,et al.Gene expression. MicroRNA control of protein expression noise[J]. Science,2015,348(6230):128-132.
11	SCHWERTZ H,KSTER S,KAHR WH,et al.Anucleate platelets generate progeny[J]. Blood,2010,115(18):3801-3809.
12	BROGREN H,KARLSSON L,ANDERSSON M,et al.Platelets synthesize large amounts of active plasminogen activator inhibitor1[J]. Blood,2004,104(13):3943-3948.
13	SCHWERTZ H,TOLLEY ND,FOULKS JM,et al.Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets[J]. J Exp Med,2006,203(11):2433-2440.
14	DENIS MM,TOLLEY ND,BUNTING M,et al.Escaping the nuclear confines:signal-dependent pre-mRNA splicing in anucleate platelets[J]. Cell,2005,122(3):379-391.
15	BRUCHOVA H,MERKEROVA M,PRCHAL JT.Aberrant expression of microRNA in polycythemia vera[J]. Haematologica,2008,93(7):1009-1016.
16	LANDRY P,PLANTE I,OUELLET DL,et al.Existence of a microRNA pathway in anucleate platelets[J]. Nat Struct Mol Biol,2009,16(9):961-966.
17	NAGALLA S,SHAW C,KONG X,et al.Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity[J]. Blood,2011,117(19):5189-5197.
18	GARZON R,PICHIORRI F,PALUMBO T,et al.MicroRNA fingerprints during human megakaryocytopoiesis[J]. Proc Natl Acad Sci U S A,2006,103(13):5078-5083.
19	GEORGANTAS RW 3rd,HILDRETH R,MORISOT S,et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function:a circuit diagram of differentiation control[J]. Proc Natl Acad Sci U S A,2007,104(8):2750-2755.
20	LU,GUO S,EBERT BL,et al.MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors[J]. Dev Cell,2008,14(6):843-853.
21	NAVARRO F,GUTMAN D,MEIRE E,et al.MiR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53[J]. Blood,2009,114(10):2181-2192.
22	ICHIMURA A,RUIKE Y,TERASAWA K,et al.MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase1 during megakaryocytic differentiation of K562 cells[J]. Mol Pharmacol,2010,77(6):1016-1024.
23	O'CONNELL RM,RAO DS,CHAUDHURI AA,et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder[J]. J Exp Med,2008,205(3):585-594.
24	ROMANIA P,LULLI V,PELOSI E,et al.MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors[J]. Br J Haematol,2008,143(4):570-580.
25	EMAMBOKUS N,VEGIOPOULOS A,HARMAN B,et al.Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb[J]. EMBO J,2003,22(17):4478-4488.
26	BARROGA CF,PHAM H,KAUSHANSKY K.Thrombopoietin regulates c-Myb expression by modulating microRNA 150 expression[J]. Exp Hematol,2008,36(12):1585-1592.
27	LABBAYE C,SPINELLO I,QUARANTA MT,et al.A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis[J]. Nat Cell Biol,2008,10(7):788-801.
28	STARCZYNOWSKI DT,KUCHENBAUER F,ARGIROPOULOS B,et al.Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype[J]. Nat Med,2010,16(1):49-58.
29	STARCZYNOWSKI DT,KUCHENBAUER F,WEGRZYN J,et al.MicroRNA-146a disrupts hematopoietic differentiation and survival[J]. Exp Hematol,2011,39(2):167-178.
30	GIRARDOT M,PECQUET C,BOUKOUR S,et al.MiR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets[J]. Blood,2010,116(3):437-445.
31	OSMAN A,FLKER K.Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes[J]. Platelets,2011,22(6):433-441.
32	DAHIYA N,SARACHANA T,VU L,et al.Platelet microRNAs:an overview[J]. Transfus Med Rev,2015,29(4):215-219.
33	SHI R,ZHOU X,JI WJ,et al.The emerging role of miR-223 in platelet reactivity:implications in antiplatelet therapy[J]. Biomed Res Int,2015,2015:981841.
34	BRUCHOVA H,MERKEROVA M,PRCHAL JT,et al.Aberrant expression of microRNA in polycythemia vera[J]. Haematologica,2008,93(7):1009-1016.
35	LUO M,LI R,DENG X,et al.Platelet-derived miR-103b as a novel biomarker for the early diagnosis of type 2 diabetes[J]. Acta Diabetol,2015,52(5):943-949.

15种高表达的血小板miRNA（从高到低排序）	差异性表达的miRNA
hsa-miR-223	hsa-miR-190
hsa-miR-26b	hsa-miR-584
hsa-miR-26a	hsa-miR-320a
hsa-miR-23a	hsa-miR-144
hsa-miR-126	hsa-miR-320c
hsa-miR-21	hsa-miR-320d
hsa-let-71	hsa-miR-376a
hsa-miR-22	hsa-miR-320b
hsa-miR-24	hsa-miR-625
hsa-miR-720	hsa-miR-136
hsa-miR-16	hsa-miR-376c
hsa-miR-23b	hsa-miR-337-3p
hsa-miR-142-3p	hsa-miR-411
hsa-miR-142-5p	hsa-miR-34b
hsa-miR-191	hsa-miR-376a

15种高表达的血小板miRNA（从高到低排序）	差异性表达的miRNA
hsa-miR-223	hsa-miR-190
hsa-miR-26b	hsa-miR-584
hsa-miR-26a	hsa-miR-320a
hsa-miR-23a	hsa-miR-144
hsa-miR-126	hsa-miR-320c
hsa-miR-21	hsa-miR-320d
hsa-let-71	hsa-miR-376a
hsa-miR-22	hsa-miR-320b
hsa-miR-24	hsa-miR-625
hsa-miR-720	hsa-miR-136
hsa-miR-16	hsa-miR-376c
hsa-miR-23b	hsa-miR-337-3p
hsa-miR-142-3p	hsa-miR-411
hsa-miR-142-5p	hsa-miR-34b
hsa-miR-191	hsa-miR-376a

miRNA	靶点	在血小板生成中的作用	相关文献
miR-155	ETS-1,MEIS-1	通过抑制巨核细胞的生成来减少血小板数量	[19][23][24]
miR-150	C-MYB	通过促进巨核细胞的生成来增加血小板数量	[20][25][26]
miR-146a	TRAF6,IL-6,TNF-ɑ,IFN-β,IL-1β	在巨核细胞核血小板生成过程中起调节作用	[27][28][29]
miR-34a	MAPPK1	通过促进造血干细胞形成巨核细胞集落,从而促进巨核细胞核血小板的生成	[21][22]
miR-28	MPL	通过抑制巨核细胞的生成来减少血小板数量	[30]
miR-27a	RUNX1	联合Runxl促进巨核细胞生成,增加血小板数量	[31]
miR-125b-2	DICER1,ST18	对巨核细胞的分化和血小板的生成起调节作用	[32]

miRNA	靶点	在血小板生成中的作用	相关文献
miR-155	ETS-1,MEIS-1	通过抑制巨核细胞的生成来减少血小板数量	[19][23][24]
miR-150	C-MYB	通过促进巨核细胞的生成来增加血小板数量	[20][25][26]
miR-146a	TRAF6,IL-6,TNF-ɑ,IFN-β,IL-1β	在巨核细胞核血小板生成过程中起调节作用	[27][28][29]
miR-34a	MAPPK1	通过促进造血干细胞形成巨核细胞集落,从而促进巨核细胞核血小板的生成	[21][22]
miR-28	MPL	通过抑制巨核细胞的生成来减少血小板数量	[30]
miR-27a	RUNX1	联合Runxl促进巨核细胞生成,增加血小板数量	[31]
miR-125b-2	DICER1,ST18	对巨核细胞的分化和血小板的生成起调节作用	[32]

[1]	王蓉, 邢连翔, 黄克亮, 李欣. miR-374靶向下调TRIM35表达可促进乳腺癌细胞增殖和侵袭[J]. 检验医学, 2023, 38(9): 812-817.
[2]	徐刚强, 晏利红. 冷凝集致单纯假性血小板减少1例报道并文献复习[J]. 检验医学, 2023, 38(9): 905-908.
[3]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[4]	潘信, 吕颖, 李阳, 李荣国. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7): 640-646.
[5]	段丽丽, 蒋唱, 周冬梅. PLR在抗核抗体阳性强直性脊柱炎患者中的临床价值[J]. 检验医学, 2023, 38(7): 669-674.
[6]	郭洁, 李海霞, 李小云. 术前外周血红细胞分布宽度/血小板计数比值与子宫内膜癌患者预后的相关性[J]. 检验医学, 2023, 38(7): 675-679.
[7]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[8]	张莹, 景丽娟, 李丽. HBV携带者外周血单个核细胞miR-138表达与病毒增殖的关系[J]. 检验医学, 2023, 38(6): 559-562.
[9]	刘灿, 罗伶俐, 付敏. ASO阳性HSPN患儿NLR、PLR、MPR和免疫球蛋白检测的临床价值[J]. 检验医学, 2023, 38(6): 590-593.
[10]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[11]	陈艺, 王稼, 徐志伟, 翟亚萍, 轩伟霞. 不同抗凝剂对体外中性粒细胞吞噬、活化和凋亡功能的影响[J]. 检验医学, 2023, 38(5): 479-483.
[12]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[13]	袁爽, 冯磊, 郭小芬, 付小玲, 许静, 刘弘扬. 子宫内膜癌组织miR-433的表达及其与化疗敏感性的关系[J]. 检验医学, 2023, 38(4): 337-341.
[14]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[15]	刘冲, 张静, 李胜, 赵奇. miR-335和Fra-1在乳腺癌中的表达及相互关系[J]. 检验医学, 2023, 38(2): 143-147.